Skip to content
Screener

Glaukos GKOS Financing Cash Flow

Financing Cash Flow at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
-$8.78B-54.9%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
-$1.22B-8.5%
Sight Sciences, Inc. logo
Sight Sciences, Inc.SGHT
$474K-2.3%
AbbVie logo
AbbVieABBV
$919M+173%
Schering-Plough logo
Schering-PloughSGP
$157.76M+215%
Bausch + Lomb logo
Bausch + LombBLCO
$34M-62.2%

Other financials

Income statement

See full
Revenue$185.6M+49.5%
Gross profit$151.6M+55.9%
Operating income-$17.3M+23.9%
Net income-$18.4M+6.5%
EPS (diluted)-$0.31+8.8%

Balance sheet

See full
Cash & equivalents$114.5M+13.6%
Total debt$105.9M-1.4%
Total equity$682.5M-10.8%
Total assets$920.5M-6.7%

Cash flow

See full
Operating cash flow$14.8M
CapEx$2.7M+132%
Free cash flow-$16.5M+19.4%

Valuation

See full
Market cap$10.09B+98.7%
Enterprise value$10.08B+98.3%
P/S16.5×+4.7×

Profitability

See full
Gross margin61%-15.4pp
Operating margin-31.6%+22.2pp
Net margin-30.7%+23.3pp
FCF margin-13.2%-3.9pp

Returns & leverage

See full
Return on equity-26%-11,301pp
Debt / equity0.2×0.0×
Current ratio-0.5×

Where this comes from

Reported directly by Glaukos in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.

The source filing: Glaukos’s 10-Q, filed July 29, 2026.

Filed
Jul 29, 2026, 5:06 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-324201
Line itemSix Months Ended June 30, 2026Six Months Ended June 30, 2025
Proceeds from share purchases under Employee Stock Purchase Plan2,3812,961
Payment of employee taxes related to vested restricted stock units(8,412)(7,294)
Principal paid on finance lease(640)(526)
Net cash provided by financing activities16,7604,195
Effect of exchange rate changes on cash and cash equivalents(1,302)(4,635)
Net increase (decrease) in cash, cash equivalents and restricted cash22,953(69,712)
Cash, cash equivalents and restricted cash at beginning of period94,647174,359
Cash, cash equivalents and restricted cash at end of period$117,600$104,647

Item 1. Financial Statements

FAQ

What is Glaukos's financing cash flow?
Glaukos (GKOS) reported financing cash flow of $991K in Q2 2026.
How has Glaukos's financing cash flow changed year-over-year?
Glaukos's financing cash flow decreased by 55.9% year-over-year, from $2.25M to $991K.
What is the long-term trend for Glaukos's financing cash flow?
Over 4 years (2021 to 2025), Glaukos's financing cash flow has grown at a -25.8% compound annual growth rate (CAGR), from $39.26M to $11.89M.
What does financing cash flow mean?
Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.

Ask your AI about Glaukos's financing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude